Business Description
OptimizeRx Corp
NAICS : 621610
SIC : 8099
ISIN : US68401U2042
Description
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.45 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | -1.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.57 | |||||
| Beneish M-Score | -3.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.7 | |||||
| 3-Year EBITDA Growth Rate | -577.5 | |||||
| 3-Year EPS without NRI Growth Rate | -68 | |||||
| 3-Year FCF Growth Rate | -3 | |||||
| 3-Year Book Growth Rate | 28.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14.59 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.97 | |||||
| 9-Day RSI | 28.28 | |||||
| 14-Day RSI | 36.01 | |||||
| 3-1 Month Momentum % | 10.4 | |||||
| 6-1 Month Momentum % | -25.87 | |||||
| 12-1 Month Momentum % | -64.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.23 | |||||
| Quick Ratio | 3.23 | |||||
| Cash Ratio | 1.11 | |||||
| Days Sales Outstanding | 113.99 | |||||
| Days Payable | 22.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.1 | |||||
| Shareholder Yield % | -40.26 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.6 | |||||
| Operating Margin % | -13.47 | |||||
| Net Margin % | -27.41 | |||||
| FCF Margin % | -1.27 | |||||
| ROE % | -20.12 | |||||
| ROA % | -14.71 | |||||
| ROIC % | -6.72 | |||||
| 3-Year ROIIC % | -8.87 | |||||
| ROC (Joel Greenblatt) % | -139 | |||||
| ROCE % | -18.19 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 15.38 | |||||
| PE Ratio without NRI | 28.54 | |||||
| PS Ratio | 1.12 | |||||
| PB Ratio | 0.84 | |||||
| EV-to-EBIT | -4.01 | |||||
| EV-to-EBITDA | -4.74 | |||||
| EV-to-Revenue | 1.24 | |||||
| EV-to-Forward-Revenue | 1.09 | |||||
| EV-to-FCF | -97.59 | |||||
| Price-to-GF-Value | 0.26 | |||||
| Price-to-Projected-FCF | 1.08 | |||||
| Price-to-Median-PS-Value | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -24.94 | |||||
| FCF Yield % | -1.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OptimizeRx Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 88.18 | ||
| EPS (TTM) ($) | -1.34 | ||
| Beta | 1.49 | ||
| 3-Year Sharpe Ratio | -0.8 | ||
| 3-Year Sortino Ratio | -1.01 | ||
| Volatility % | 55.87 | ||
| 14-Day RSI | 36.01 | ||
| 14-Day ATR ($) | 0.412783 | ||
| 20-Day SMA ($) | 5.7165 | ||
| 12-1 Month Momentum % | -64.08 | ||
| 52-Week Range ($) | 3.78 - 16.645 | ||
| Shares Outstanding (Mil) | 18.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OptimizeRx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OptimizeRx Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
OptimizeRx Corp Frequently Asked Questions
What is OptimizeRx Corp(OPRX)'s stock price today?
The current price of OPRX is $5.28. The 52 week high of OPRX is $16.65 and 52 week low is $3.78.
When is next earnings date of OptimizeRx Corp(OPRX)?
The next earnings date of OptimizeRx Corp(OPRX) is 2025-03-12.
Does OptimizeRx Corp(OPRX) pay dividends? If so, how much?
OptimizeRx Corp(OPRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers